Jim Cramer's Stop Trading! Buy Celgene

Cramer sees Revlimid data as a huge opportunity.
Author:
Publish date:

Buy

Celgene

(CELG) - Get Report

, Jim Cramer said Monday on

CNBC's

"Stop Trading!" segment.

Cramer said he believes that research unveiled this weekend on the company's Revlimid cancer drug shows that the stock has great upside. But Monday's flat stock performance shows the development is a "tree falling in the woods." Cramer believes the stock, up 50% over the last year at $61 and change, is "ready to roll again."

Cramer also likes

Wal-Mart

(WMT) - Get Report

, saying the stock's second straight 3% daily gain isn't a reason to wait for a pullback. Cramer said he agrees with an HSBC analyst's call that the stock could go to $61 in the next year from $50 and change Monday.

Cramer believes a Bear Stearns analyst's upgrade of

Sirius

(SIRI) - Get Report

is a "big call" and that the analyst's track record should make investors take notice. Cramer said the call isn't working Monday, with the stock down 3 cents at $2.85, but he believes it could turn around and hit Bear's $4 price target.

At the time of publication, Cramer had no positions in stocks mentioned.

Jim Cramer is a director and co-founder of TheStreet.com. He contributes daily market commentary for TheStreet.com's sites and serves as an adviser to the company's CEO. Outside contributing columnists for TheStreet.com and RealMoney.com, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for

Action Alerts PLUS. Watch Cramer on "Mad Money" weeknights on CNBC. Click

here to order Cramer's latest book, "Mad Money: Watch TV, Get Rich," click

here to order his book, "Real Money: Sane Investing in an Insane World," click

here to get his second book, "You Got Screwed!" and click

here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by

clicking here.

TheStreet.com has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from TheStreet.com.